Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
637actual
Sites
32
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-30 | actual | When the study began enrolling |
| Primary completion | 2025-09-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Primary outcome
what the primary-completion date above is the date OFdisease activity status at the time of patient visit to the doctor measured with SLEDAI-2K, expressed as the mean SLEDAI-2K total score at Visit 2.
measured patient's visit to the doctor (Visit 2 -prospective data collection)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed